Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for East Bridge Capital Master Fund Ltd & East Bridge Capital Master Fund I Ltd
19-03-2020
Bigul

Jubilant Life Sciences Ltd - 530019 - Fixes Record Date for Interim Dividend

Jubilant Life Sciences Ltd has informed BSE that the Company has fixed March 11, 2020 as the Record Date for the purpose of Payment of Interim Dividend.The interim dividend will be paid / despatched on or before March 27, 2020.
28-02-2020
Bigul

Jubilant Life Sciences Ltd - 530019 - Announcement under Regulation 30 (LODR)-Dividend Updates

Declaration of Interim Dividend - Financial Year 2019-20 Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Board of Directors has, at its meeting held today i.e. February 27, 2020, declared interim dividend @ 500% i.e. Rs. 5 per Equity Share of Re. 1 each on the paid-up Equity Share capital of the Company for the Financial Year 2019-20. In terms of Regulation 42 of the Listing Regulations, the Board has fixed Wednesday, March 11, 2020, as the 'Record Date' for the purpose of ascertaining eligibility of the shareholders for payment of interim dividend. The interim dividend will be paid / despatched on or before Friday, March 27, 2020. This is for information and record.
27-02-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Board to consider Interim Dividend

Jubilant Life Sciences Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on February 27, 2020, inter-alia to consider a proposal for declaration of interim dividend for the financial year 2019-20.Further, pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company shall remain closed from February 21, 2020 to February 29, 2020 (both days inclusive).
20-02-2020
Bigul

Jubilant Life Sciences Ltd - 530019 - Board Meeting Intimation for Intimation Of Board Meeting - February 27, 2020

JUBILANT LIFE SCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/02/2020 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 27, 2020, to inter-alia consider a proposal for declaration of interim dividend for the financial year 2019-20. Further, pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company shall remain closed from Friday, February 21, 2020 to Saturday, February 29, 2020 (both days inclusive). This is for information and record.
20-02-2020
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Pursuant to the provisions of Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has issued duplicate share certificates to the members as per the attachment. This is for your information and record.
07-02-2020
Bigul

Earnings Call Transcript - Jubilant Life Sciences

Full Earnings Transcript: Conference Call between Management and Analysts
07-02-2020
Bigul

Jubilant Life Sciences Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication

In continuation of our letter dated January 31, 2020, we enclose copies of the Unaudited Consolidated Financial Results for the quarter ended December 31, 2019 published on February 1, 2020 in MINT (English) and HINDUSTAN (Hindi).
03-02-2020

Jubilant Life Sciences Q3 net profit down 24% to Rs 203.38cr

Net sales during the quarter under review stood at Rs 2,279.89 crore, down 3.11 per cent, as against Rs 2,353.08 crore in the corresponding period a year ago.
31-01-2020
Bigul

Jubilant Life Sciences Ltd - 530019 - Results For The Quarter Ended December 31, 2019

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended December 31, 2019 were approved by the Board of Directors of the Company at its meeting held today at 1.00 p.m. and concluded at 2.45 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2019; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and 3. Copies of the Press Release and Presentation. We request you to take the same on records.
31-01-2020
Next Page
Close

Let's Open Free Demat Account